Home    About NDEI   Site Map   FAQ   Contact Us   Feedback   
       Advanced Search    
Home
CME on Demand
Live CME Events
Case Studies
Slide Library
Literature Alerts
Clinical Insights
PodCasts
Pharmacist CE
Managed Care
Calendar of Events
Multimedia Presentations
Treatment Guidelines
Clinical Trials
Other CME
Other Resources
Product Indications
Glossary


Your Online Resource for Diabetes Treatment
Welcome to NDEI.org, the website of the National Diabetes Education Initiative.          Register May 15, 2008
What's New
NDEI One-Minute Survey
What Clinical Tools are valuable to your practice?
What Clinical Tools do you need/desire?

CME Interactive Case Study 
A 17-Year-Old Hispanic Male High School Football Player With Blurred Vision and Fatigue

Faculty: Anne Peters, MD

.75 AMA PRA Category 1 Credits


CCMDweb Interactive Case Study

CCMDweb.org Interactive Case Study 
Secondary Prevention of Cardiovascular Disease:
Looking Beyond the LDL
Knowledge of appropriate management of patients with type 2 diabetes and established coronary artery disease

Faculty: Peter Libby, MD

1.5 AMA PRA Category 1 Credits™


New Slides of the month
View our Slide Library. The NDEI Slide Library includes slides on type 2 diabetes and related topics. All are searchable by topic, author, title, keywords, and slide notes. Slides can be downloaded directly to your hard drive or emailed to you.

Changing Paradigms in the Prevention and Treatment of Type 2 Diabetes: Results From Recent Pivotal Trials

Faculty: Edward S. Horton, MD; Hertzel C. Gerstein, MD, MSc, FRCPC; Steven M. Haffner, MD; Theodore Mazzone, MD

The Endocrine Society designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits.



Live Activities
Dinner Meetings
Managing the Complexities of Type 2 Diabetes:
A Roadmap for Improving Patient Care
A Case-Based Interactive CME/CE Dinner Program
Tuesday, March 18, 2008 San Antonio, Texas
Thursday, March 20, 2008 Baltimore, Maryland
Wednesday, March 26, 2008 Seattle, Washington
Tuesday, April 8, 2008 New Orleans, Louisiana
Tuesday, April 8, 2008 Richmond, Virginia
Wednesday, April 9, 2008 Atlanta, Georgia
Thursday, April 10, 2008 Orlando, Florida
Tuesday, April 15, 2008 Cincinnati, Ohio
Thursday, April 17, 2008 Ann Arbor, Michigan
Tuesday, April 22, 2008 Rochester, New York
Thursday, April 24, 2008 Stamford, Connecticut
Tuesday, April 29, 2008 Indianapolis, Indiana
Tuesday, May 6, 2008 St Louis, Missouri
Thursday, May 29, 2008 Denver, Colorado
Thursday, May 29, 2008 Birmingham, Alabama


On Demand Activities

Diabetes Expert Forum—The Role of Incretin Therapy in Your Practice
Faculty: Mark W. Stolar, MD; Silvio E. Inzucchi, MD; Frank Lavernia, MD

1.75 AMA PRA Category 1 Credits

This activity has been reviewed and is acceptable for up to 2.75 Prescribed credits by the American Academy of Family Physicians


Type 2 Diabetes, Metabolic Syndrome, and CVD: Clinical Implications of Recent Pivotal Trials
Presented by Silvio E. Inzucchi, MD Professor of Medicine Yale University School of Medicine New Haven, Connecticut
Incretins and Glycemic Control: Understanding the Science for Better Diabetes Management
Presented by: Edward Horton, MD (Chairman), Charles Burant, MD, PhD, and John Buse, MD, PhD
 


Interactive Case Studies
 

A 54-Year-Old Taxi Driver Who Presents for Reassessment of His Type 2 Diabetes and New Dyspnea on Exertion Authored by Silvio E. Inzucchi, MD

Earn 0.75 AMA PRA Category 1 Credit™-Free




FDA Alerts
 

FDA: injectable heparin products and heparin flush solutions may be contaminated with oversulfated chondroitin sulfate

The FDA  recalls of injectable heparin products and heparin flush solutions that may be contaminated with oversulfated chondroitin sulfate (OSCS).   Affected heparin products have been found in medical care facilities in one state since the recall announcement.  Although product recall instructions were widely distributed, they may not have been fully acted upon at all sites where heparin is used.  There have been many reports of deaths associated with allergic or hypotensive symptoms after heparin administration.  Please see FDA link at http://www.fda.gov/cder/drug/infopage/heparin/adverse_events.htm


The FDA asks that health professionals and facilities review and examine all drug/device storage areas, including emergency kits, dialysis units and automated drug storage cabinets to ensure that all of the recalled heparin products have been removed and are no longer available for patient use. 
 

Click here to view the entire press release.

 





  

Quick Links to the Most Timely Content on the Internet

The links below search the National Library of Medicine's Medline database (PubMed) for abstracts posted during the previous 7 calendar days.  The links are updated daily to reflect the addition of new content.

Please contact us through info@ndei.org with suggestions for additional search terms.

Search for new abstracts posted within the past:

Insulin Resistance Patient Management Alpha-Glucosidase Inhibitors
Metabolic Syndrome Novel Therapies Diabetes and Statins
Diabetes and Cardiovascular Disease Thiazolidinediones Diabetes and ACE Inhibitors
Beta-cell Function Biguanides Diabetes and Dyslipidemia
Glycemic Control Sulfonylureas Epidemiology of Diabetes






Sponsored by
Professional Postgraduate Services ®
Secaucus, NJ

Supported by educational grants from Takeda Pharmaceuticals North America, Inc. and Merck & Co., Inc.


The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose
Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE
Diabetes Care. 31(1):108-13
Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%
Pani LN, Nathan DM, Grant RW.
Diabetes Care. 31(3):386-90
Reinventing type 2 diabetes: pathogenesis, treatment, and prevention
Unger RH.
JAMA. 299(10):1185-7
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.
Curr Med Res Opin. 24(2):537-50

 
Supported by educational grants from Takeda Pharmaceuticals North America, Inc. and Merck & Co., Inc.
Professional Postgraduate Services is a business unit of KnowledgePoint360 Group, LLC, Secaucus, NJ.
Copyright © 2007 Professional Postgraduate Services®. All rights reserved. - Disclaimer Statement - Privacy Statement